Seeking Alpha

KarinCA's  Instablog

KarinCA
Send Message
I'm an independent writer/trader/investor whose primary interests are in the stem cell and biotech arena. My secondary interest is in oil/energy speculation. I do venture elsewhere at times. There’s an option to follow me at the top of any article I write. Click it and you’ll also see an option... More
View KarinCA's Instablogs on:
  • US Army Adopts And Deploys Provodine® From Microdermis To Fight Ebola

    This new anti-infective will end up preventing a lot of healthcare workers from contracting Ebola. It's a step in the right direction.

    "The antiseptic skin product, Provodine®, is being applied as a final "molecular barrier" to viral exposure for healthcare workers and emergency responders using traditional layers of protective equipment. To date a total of 335 relief workers have died while fighting to prevent the transmission of Ebola virus infections in West Africa. Skin coverage is an issue. Unlike most branded antiseptic products - which are contra-indicated for eye, mucosal surfaces (nose and mouth), ear and genitals - Provodine® can be safely used on the most sensitive areas of the body."

    Too bad the company is privately held. I wonder how many mistake this product for a cure?

    Dec 01 3:50 PM | Link | 1 Comment
  • Four “Ebola” Related Companies Suspended By SEC

    SEC files Order of Suspension of Trading of the following companies:

    Bravo Enterprises Ltd. OGNG

    Immunotech Laboratories, Inc. IMMB

    Myriad Interactive Media, Inc. MYRY

    Wholehealth Products, Inc. GWPC

    Disclosure: The author has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

    Nov 21 11:17 AM | Link | Comment!
  • $CTIX - Brilacidin For Oral Mucositis

    Another update from 10Q filed 11.10.14

    https://www.sec.gov/Archives/edgar/data/1355250/000147793214005934/ctix_10q.htm

    In animal models of oral mucositis, an oral rinse containing Brilacidin was shown to reduce the occurrence of severe ulcerative oral mucositis by more than 90% compared to placebo. Brilacidin and related compounds have shown antibacterial, anti-biofilm and anti-inflammatory properties in various pre-clinical studies. We believe that the combination of these attributes contribute to the efficacy of Brilacidin in these animal models. In December 2013, the Company filed an application with the U.S. Food and Drug Administration requesting Orphan Drug designation for Brilacidin as a drug candidate for the prevention oral mucositis in head and neck cancer. FDA has advised the company that the data would indicate the Brilacidin-OM could treat not only patients that have radiation induced OM but potentially treat as well patients with chemotherapy-induced OM. Therefore the target population would exceed the number of patients that would qualify for orphan drug designation.

    In September 2014 Cellceutix filed an IND (Investigative New Drug application) for a planned trial titled "Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Brilacidin Oral Rinse Administered Daily for 7 Weeks in Attenuating Oral Mucositis in Patients with Head and Neck Cancer Receiving Concurrent Chemotherapy and Radiotherapy". On October 13, 2014 Cellceutix announced the acceptance of its IND (Investigational New Drug Application) by the Food and Drug Administration for the treatment of Oral Mucositis with Brilacidin. Presently sites are being set up, supplied, and trained. We expect our first patient to be enrolled in December 2014.

    Cellceutix related articles by KarinCA

    Regulatory Support Creates Opportunity For Antibiotic Makers Otonomy And Cellceutix 9.25.14

    Update: Cellceutix Calls Out To President Obama About Brilacidin 9.21.14

    Update: Cellceutix's Antibiotic Brilacidin Should Move Share Price Before Kevetrin Or Prurisol 9.14.14

    Interview With Leo Ehrlich, Cellceutix CEO Following Acquisition Of PolyMedix Assets 9.18.13

    An Interview With Leo Ehrlich, Cellceutix CEO 3.14.13

    Which Drug Moves Cellceutix First: Kevetrin Or Prurisol? 1.28.13

    Why The Aspire Deal Is A Winner For Cellceutix Shareholders 12.18.12

    Watch Cellceutix Closely For Potential Catalysts In 2013 12.10.12

    Disclosure: The author is long CTIX.

    Nov 18 1:15 PM | Link | Comment!
Full index of posts »
Latest Followers

StockTalks

More »

Latest Comments


Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.